Trials / Completed
CompletedNCT00558272
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 139 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD0530 | Daily oral dose |
| DRUG | Zoledronic Acid |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2010-01-01
- Completion
- 2012-08-01
- First posted
- 2007-11-14
- Last updated
- 2013-05-27
- Results posted
- 2011-06-27
Locations
28 sites across 8 countries: United States, Canada, Denmark, Norway, Portugal, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00558272. Inclusion in this directory is not an endorsement.